Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial

AIMS: This two‐part, double‐blind, double‐dummy, randomized, placebo‐controlled trial (83 sites) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed‐dose combinations (FDCs) in Japanese patients with type 2 diabetes mellitus (T2DM) who were poorly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes Obes Metab
Hauptverfasser: Kaku, Kohei, Haneda, Masakazu, Tanaka, Yuko, Lee, Ganghyuck, Shiki, Kosuke, Miyamoto, Yuki, Solimando, Fernando, Lee, Jisoo, Lee, Christopher, George, Jyothis
Format: Artigo
Sprache:Inglês
Veröffentlicht: Blackwell Publishing Ltd 2018
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585831/
https://ncbi.nlm.nih.gov/pubmed/30091172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13496
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge